Importance of glycolysis and oxidative phosphorylation in advanced melanoma

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Ho, Jonhan ^a   de Moura, Michelle B ^a   Lin, Yan ^b   Vincent, Garret ^a   Thorne, Stephen ^c   Duncan, Lyn M ^d   Hui Min, Lin ^b   Kirkwood, John M ^a   Becker, Dorothea ^a   Van Houten, Bennett ^a   Moschos, Stergios J ^a,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Glycolysis; Lactate dehydrogenase; Melanoma; Mitochondria; Monocarboxylate transporters; Oxidative phosphorylation

Indexed keywords

LACTATE DEHYDROGENASE; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; GLYCOLYSIS; HUMAN; HUMAN CELL; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; MELANOMA; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CELL LINE, TUMOR; DISEASE PROGRESSION; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; L-LACTATE DEHYDROGENASE; MELANOMA; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASM STAGING; NEVUS; OXIDATIVE PHOSPHORYLATION; OXIDATIVE PHOSPHORYLATION COUPLING FACTORS;

EID: 84867128553     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-76     Document Type: Article

References (41)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
3. Elia U, Flescher E. Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment. Curr Pharm Biotechnol 2012, Jun 1. [Epub ahead of print].
4. Rodríguez-Enríquez S, Gallardo-Pérez JC, Marín-Hernández A, Moreno-Sánchez R. The Warburg Hypothesis and the ATP Supply In Cancer Cells Is Oxidative Phosphorylation impaired in malignant neoplasias?. Curr Pharm Biotechnol 2012, Jun 1. [Epub ahead of print].
5. Barbi de Moura M, Vincent G, Fayewicz SL, Bateman N, Hood BL, Sun M, Suhan J, Duensing S, Yin Y, Sander C, et al. Mitochondrial Respiration - an Important Therapeutic Target in Melanoma. PLoS One 2012, 7(8):e40690. 10.1371/journal.pone.0040690, 3422349, 22912665.
6. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 2011, 286:42626-42634. 10.1074/jbc.M111.282046, 3234981, 21998308.
7. Qin JZ, Xin H, Nickoloff BJ. Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death. Biochem Biophys Res Commun 2010, 398:146-152. 10.1016/j.bbrc.2010.06.057, 20599741.
8. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 1989, 49(14):3759-3764.
9. Nakajima EC, Van Houten B. Metabolic symbiosis in cancer: Refocusing the Warburg lens. Mol Carcinog 2012, Jan 6: [Epub ahead of print].
10. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942. 2582933, 19033663.
11. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000, 18:3782-3793.
12. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002, 20:125-133. 10.1200/JCO.20.1.125, 11773161.
13. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745. 10.1200/JCO.2006.06.0483, 16966688.
14. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, et al. BEAM: a randomized phase ii study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012, 30:34-41. 10.1200/JCO.2011.34.6270, 22124101.
15. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ. Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (LBA9012) [abstract]. J Clin Oncol 2009, 27:18s.
16. Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE, et al. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One 2012, 7:e29798. 10.1371/journal.pone.0029798, 3256171, 22253786.
17. Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, Becker D. Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation. Cancer Biol Ther 2009, 8:1815-1825. 10.4161/cbt.8.19.9435, 19684476.
18. Nazarian RM, Prieto VG, Elder DE, Duncan LM. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 2010, 37(Suppl 1):41-47.
19. Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C, Acquafondata M, et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol 2010, 41:1286-1298. 10.1016/j.humpath.2010.02.007, 20561671.
20. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995, 48:876-878. 10.1136/jcp.48.9.876, 502883, 7490328.
21. Hsu MY, Kohler MM, Barolia L, Bondar RJ. Separation of five isoenzymes of serum lactate dehydrogenase by discontinuous gradient elution from a miniature ion-exchange column. Clin Chem 1979, 25:1453-1458.
22. Qian W, Van Houten B. Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods 2010, 51:452-457. 10.1016/j.ymeth.2010.03.006, 20347038.
23. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011, 2:49. 3161244, 21904528.
24. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996, 271:32529-32537. 10.1074/jbc.271.51.32529, 8955077.
25. Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H. Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 2009, 34:e962-e964. 10.1111/j.1365-2230.2009.03706.x, 20055873.
26. Yusenko MV, Ruppert T, Kovacs G. Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci 2010, 6:213-224. 2862395, 20440404.
27. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Rev Drug Discov 2011, 10:767-777.
28. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002, 1:617-628.
29. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983, 51:840-843. 10.1002/1097-0142(19830301)51:5<840::AID-CNCR2820510516>3.0.CO;2-7, 6821850.
30. Khurana P, Tyagi N, Salahuddin A, Tyagi SP. Serum lactate dehydrogenase isoenzymes in breast tumours. Indian J Pathol Microbiol 1990, 33:355-359.
31. Giannoulaki EE, Kalpaxis DL, Tentas C, Fessas P. Lactate dehydrogenase isoenzyme pattern in sera of patients with malignant diseases. Clin Chem 1989, 35:396-399.
32. Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y. A Comparative Study of Gene-Expression Data of Basal Cell Carcinoma and Melanoma Reveals New Insights about the Two Cancers. PLoS One 2012, 7:e30750. 10.1371/journal.pone.0030750, 3266277, 22295108.
33. Berridge MV, Tan AS. Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res 2010, 13(2-3):139-141.
34. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 2012, 25:375-383. 10.1111/j.1755-148X.2012.00989.x, 22360810.
35. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000, 350(Pt 1):219-227. 1221245, 10926847.
36. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006, 281:9030-9037.
37. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129:111-122. 10.1016/j.cell.2007.01.047, 17418790.
38. de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010, 51:391-405.
39. Mazure NM, Brahimi-Horn MC, Pouyssegur J. Hypoxic mitochondria: accomplices in resistance. Bull Cancer 2011, 98:40-46.
40. Hendifar AE, Chawla SP, Quon D, Chua VS, Fernandez L, Nagre S, Okunnu M, Chmielowski B, Singh AS, Akmaev S, et al. Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity [abstr 3015]. J Clin Oncol 2012, 27.
41. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouyssegur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA 2011, 108:16663-16668. 10.1073/pnas.1106123108, 3189052, 21930917.